Cell-free circulating epimarks in cancer monitoring - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Epigenomics Année : 2020

Cell-free circulating epimarks in cancer monitoring

Dominique Heymann

Résumé

Cancer numbers increasing, cases heterogeneity and the drug resistance emergence have pushed scientists to search for innovative solutions for patients and epimutations can be one. Methylated DNA, modified nucleosomes and noncoding RNAs are found in all cells, including tumor cells. They are intracellular actors but also have intercellular communication roles, being released in extracellular environment and in different body fluids. Here, we reviewed current literature on the use of these blood circulating epimarks in cancer monitoring. What stands out is that epimarkers must be considered as 'real time' images of the tumor, and can be isolated without invasive methods. In the future, the real challenge lies in the development of specific, sensitive, fast and clinically applicable detection and analysis methods of epimarkers.

Domaines

Cancer
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-02484725 , version 1 (19-02-2020)

Identifiants

Citer

Manon Duforestel, Josephine Briand, Gwenola Bougras-Cartron, Dominique Heymann, Jean-Sébastien Frenel, et al.. Cell-free circulating epimarks in cancer monitoring. Epigenomics, 2020, 12 (2), pp.145-155. ⟨10.2217/epi-2019-0170⟩. ⟨inserm-02484725⟩
52 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More